An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union
Meier A., Faulkner SD., Schoonderbeek C., Jong B., Kung J., Brindley D., Barker R.
© 2016 American Society for Clinical Pharmacology and Therapeutics One of the key advantages of adaptive licensing (AL) is to align the licensing of new medicines more closely with patient needs for earlier access to beneficial treatments. From an innovators perspective, “earlier” market access may seem an obvious incentive to gain earlier revenue generation. However, this is offset with an “earlier” start to patent and regulatory protection periods, which, depending on the technology, disease, population, and timing of subsequent asset protection periods, can present a conflict.